Shanghai MicroPort MedBot (Group) Co., Ltd. provided revenue guidance for the six months ended June 30, 2024. for the six months, the company expects revenue will achieve a significant year-on-year growth of approximately 103% to 108% as compared to that for the six months ended 30 June 2023, which is mainly attributable to following reasons: 1. Toumai Laparoscopic Surgical Robot, the core product, has maintained its strong sales momentum in domestic market, and ranked first in the market share of domestic laparoscopic surgical robots during the Period; at the same time, Toumai has successfully completed first overseas commercial installation and achieved revenue breakthroughs. Its overseas market expansion process has been further accelerated with the cumulative overseas orders exceeding ten units especially after being awarded the certification from EU CE in May 2024; 2. The SkyWalker orthopedic surgical robot fully leveraged its synergies with MicroPort Group during the Period, gradually expanding its global presence to over 20 countries across five continents.

It achieved sales revenues in the United States, Europe, Australia, and other regions, achieving a twofold increase in sales compared to the same period last year; 3. The launch of new products contributed to an increase in revenue. Among the new products, the in-hospital promotion of the R-ONE vascular interventional robot that approved in December 2023 accelerated. The product also recorded its first installation and generated revenue during the Period.